Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment

被引:11
作者
Dhimolea, Eugen [1 ,2 ,3 ]
Simoes, Ricardo de Matos [1 ,2 ,3 ]
Kansara, Dhvanir [1 ]
Weng, Xiang [1 ]
Sharma, Shruti [1 ]
Awate, Pallavi [1 ]
Liu, Zhiyi [4 ]
Gao, Dong [5 ]
Mitsiades, Nicholas [6 ]
Schwab, Joseph H. [2 ,7 ]
Chen, Yu [5 ]
Jeselsohn, Rinath [1 ,2 ]
Culhane, Aedin C. [8 ,9 ]
Brown, Myles [1 ,2 ,10 ]
Georgakoudi, Irene [4 ]
Mitsiades, Constantine S. [1 ,2 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA
[4] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA
[5] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[6] Baylor Coll Med, Houston, TX 77030 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[9] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
[10] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA
关键词
ANDROGEN RECEPTOR GENE; BREAST-CANCER; ESTROGEN-RECEPTOR; GROWTH-FACTOR; PROSTATE-CANCER; TAMOXIFEN; INTERLEUKIN-6; RECRUITMENT; PROGRESSION; MUTATIONS;
D O I
10.1158/0008-5472.CAN-20-0571
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although hormonal therapy (HT) inhibits the growth of hormone receptor-positive (HR+) breast and prostate cancers, HT resistance frequently develops within the complex metastatic microenvironment of the host organ (often the bone), a setting poorly recapitulated in 2D culture systems. To address this limitation, we cultured HR' breast cancer and prostate cancer spheroids and patient-derived organoids in 3D extracellular matrices (ECM) alone or together with bone marrow stromal cells (BMSC). In 3D monocultures, antiestrogens and antiandrogens induced anoikis by abrogating anchorage-independent growth of HR+ cancer cells but exhibited only modest effects against tumor cells residing in the ECM niche. In contrast, BMSC induced hormone-independent growth of breast cancer and prostate cancer spheroids and restored lumen filling in the presence of HR-targeting agents. Molecular and functional characterization of BMSC-induced hormone independence and HT resistance in anchorage-independent cells revealed distinct context-dependent mechanisms. Cocul tures of ZR75-1 and LNCaP with BMSCs exhibited paracrine IL6-induced HT resistance via attenuation of HR protein expression, which was reversed by inhibition of IL6 or JAK signaling. Paracrine IL6/JAK/STAT3-mediated HT resistance was confirmed in patient-derived organoids cocultured with BMSCs. Distinctly, MCF7 and T47D spheroids retained ER protein expression in cocultures but acquired redundant compensatory signals enabling anchorage independence via ERK and PI3K bypass cascades activated in a non-IL6-dependent manner. Collectively, these data characterize the pleiotropic hormone-independent mechanisms underlying acquisition and restoration of anchorage-independent growth in H ft' tumors. Combined analysis of tumor and microenvironmental biomarkers in metastatic biopsies of HT-resistant patients can help refine treatment approaches. Significance: This study uncovers a previously underappreciated dependency of tumor cells on HR signaling for anchorage-independent growth and highlights how the metastatic microenvironment restores this malignant property of cancer cells during hormone therapy.
引用
收藏
页码:371 / 383
页数:13
相关论文
共 46 条
  • [1] Genomic correlates of clinical outcome in advanced prostate cancer
    Abida, Wassim
    Cyrta, Joanna
    Heller, Glenn
    Prandi, Davide
    Armenia, Joshua
    Coleman, Ilsa
    Cieslik, Marcin
    Benelli, Matteo
    Robinson, Dan
    Van Allen, Eliezer M.
    Sboner, Andrea
    Fedrizzi, Tarcisio
    Mosquera, Juan Miguel
    Robinson, Brian D.
    De Sarkar, Navonil
    Kunju, Lakshmi P.
    Tomlins, Scott
    Wu, Yi Mi
    Rodrigues, Daniel Nava
    Loda, Massimo
    Gopalan, Anuradha
    Reuter, Victor E.
    Pritchard, Colin C.
    Mateo, Joaquin
    Bianchini, Diletta
    Miranda, Susana
    Carreira, Suzanne
    Rescigno, Pasquale
    Filipenko, Julie
    Vinson, Jacob
    Montgomery, Robert B.
    Beltran, Himisha
    Heath, Elisabeth I.
    Scher, Howard I.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Schultz, Nikolaus
    deBono, Johann S.
    Demichelis, Francesca
    Nelson, Peter S.
    Rubin, Mark A.
    Chinnaiyan, Arul M.
    Sawyers, Charles L.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (23) : 11428 - 11436
  • [2] Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
    Bachelot, T
    Ray-Coquard, I
    Menetrier-Caux, C
    Rastkha, M
    Duc, A
    Blay, JY
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (11) : 1721 - 1726
  • [3] Baker Stacey J, 2012, Genes Cancer, V3, P658, DOI 10.1177/1947601913478972
  • [4] Becker M, 2005, MOL CANCER THER, V4, P151
  • [5] Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
    Carver, Brett S.
    Chapinski, Caren
    Wongvipat, John
    Hieronymus, Haley
    Chen, Yu
    Chandarlapaty, Sarat
    Arora, Vivek K.
    Le, Carl
    Koutcher, Jason
    Scher, Howard
    Scardino, Peter T.
    Rosen, Neal
    Sawyers, Charles L.
    [J]. CANCER CELL, 2011, 19 (05) : 575 - 586
  • [6] Endocrine resistance in breast cancer - An overview and update
    Clarke, Robert
    Tyson, John J.
    Dixon, J. Michael
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 : 220 - 234
  • [7] Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer
    Coarfa, C.
    Fiskus, W.
    Eedunuri, V. K.
    Rajapakshe, K.
    Foley, C.
    Chew, S. A.
    Shah, S. S.
    Geng, C.
    Shou, J.
    Mohamed, J. S.
    O'Malley, B. W.
    Mitsiades, N.
    [J]. ONCOGENE, 2016, 35 (18) : 2345 - 2356
  • [8] Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens
    Crawford, E. David
    Schellhammer, Paul F.
    McLeod, David G.
    Moul, Judd W.
    Higano, Celestia S.
    Shore, Neal
    Denis, Louis
    Iversen, Peter
    Eisenberger, Mario A.
    Labrie, Fernand
    [J]. JOURNAL OF UROLOGY, 2018, 200 (05) : 956 - 966
  • [9] CULIG Z, 1994, CANCER RES, V54, P5474
  • [10] Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
    Davies, Christina
    Pan, Hongchao
    Godwin, Jon
    Gray, Richard
    Arriagada, Rodrigo
    Raina, Vinod
    Abraham, Mirta
    Medeiros Alencar, Victor Hugo
    Badran, Atef
    Bonfill, Xavier
    Bradbury, Joan
    Clarke, Michael
    Collins, Rory
    Davis, Susan R.
    Delmestri, Antonella
    Forbes, John F.
    Haddad, Peiman
    Hou, Ming-Feng
    Inbar, Moshe
    Khaled, Hussein
    Kielanowska, Joanna
    Kwan, Wing-Hong
    Mathew, Beela S.
    Mittra, Indraneel
    Mueller, Bettina
    Nicolucci, Antonio
    Peralta, Octavio
    Pernas, Fany
    Petruzelka, Lubos
    Pienkowski, Tadeusz
    Radhika, Ramachandran
    Rajan, Balakrishnan
    Rubach, Maryna T.
    Tort, Sera
    Urrutia, Gerard
    Valentini, Miriam
    Wang, Yaochen
    Peto, Richard
    [J]. LANCET, 2013, 381 (9869) : 805 - 816